VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascul... (to the brain and to reduce the risk of s...)

HOME >> MEDICINE >> TECHNOLOGY

VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease

Date:11/9/2008

to the brain and to reduce the risk of stroke in patients with significant blockage in the artery. Patients in the study were treated for 12 weeks with either 100 mg of VIA-2291 or placebo, and then underwent a CEA procedure. The CEA trial was designed to provide direct evaluation of VIA- 2291's effect on inflammation by analyzing plaque removed from the carotid arteries of patients treated with VIA-2291 or placebo. The trial also measured serum biomarkers of inflammation to measure reduction in inflammation in treated patients.

Study Results

--Leukotriene Inhibition

The ACS trial demonstrated a statistically significant, dose-dependent inhibition of ex vivo stimulated LTB4 production at 12 weeks. LTB4 production was measured at trough, just before the next dose of VIA-2291 was taken, indicating a sustained pharmacological effect of the drug between doses. The secondary endpoint of change from baseline in urine Leukotriene E4 (LTE4), also showed significant inhibition at all dose levels.

The CEA trial confirmed the findings of statistically significant inhibition in leukotriene production observed in the ACS trial. In the CEA trial, LTB4 production was highly inhibited at 12 weeks (p < 0.001).

Leukotriene inhibition was seen early in both trials and was already highly significant after two weeks of drug treatment, the first time it was assessed after starting drug.

--hs-CRP Reduction

In the ACS trial, a statistically significant reduction from baseline as compared with placebo was observed in high-sensitivity C-reactive protein (hs- CRP) levels in the highest dose group of patients treated for 24 weeks. Significant reductions in hs-CRP levels were not observed in the ACS trial in patients treated for 12 weeks, perhaps due, in part, to variability in the level of hs-CRP at the baseline as a result of the recent heart attack or unstable angina.

In the CEA trial, a statistically significant reductio
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
10. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
11. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura

Post Your Comments:

(Date:5/22/2013)... , May 22, 2013 Ranbaxy ... Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on ... in recent years to address past conduct under ... Daiichi Sankyo continues to support ... the conduct of the past which led to ...

(Date:5/22/2013)... REHOVOT, Israel , May 22, 2013 ... a leading developer and provider of microRNA-based molecular diagnostics, ... President and Chief Executive Officer of Rosetta Genomics, will ... Conference taking place from June 3-6, 2013 in New ... Tuesday, June 4 th at 2:00 p.m. Eastern ...

(Date:5/22/2013)... FRANKLIN LAKES, N.J. , May 22, 2013 /PRNewswire/ ... ), a leading global medical technology company, announced today ... This is BD,s fifth Sustainability Report and it continues ... sustainability. "We believe the principles of ... communities and addressing healthcare challenges of societies — are ...

Breaking Medicine Technology:Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2 Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3 BD Issues 2012 Sustainability Report 2 BD Issues 2012 Sustainability Report 3

[0] Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives [0] Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference [0] BD Issues 2012 Sustainability Report

... efficacy and benefits of early treatment ... with liraglutide versus glimepiride, SAN FRANCISCO, ... of the American Diabetes Association (ADA),demonstrated that once-daily liraglutide when ... in,patients with type 2 diabetes, as compared to glimepiride, a ...

... Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, Inc.,(Nasdaq: ... and,commercializing novel pain management therapies, announced today the,publication ... candidate, NGX-4010, in the,journal Neurology. The paper, titled, ... Painful HIV,Neuropathy," will appear in the June 10, ...

Cached Medicine Technology:Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 2 Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 3 Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 4 NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 2 NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 3

Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology

(Date:5/22/2013)... 2013 Zensah® Compression Apparel released a ... titled "Breast pain while running affects one-third ... could help." According to the article, a British study ... amount suffer from breast pain while running but do ... issue. , Zensah emphasizes the importance for women ...

(Date:5/22/2013)... 2013 Successful Therapy for Parents ... Psychotherapy in the Silver Lake community of Los ... as progression to existing Parents and Couples counseling ... parenting therapy has always been suggested, but now ... now specializes in all aspects of relationships ...

(Date:5/22/2013)... Twenty student-led startup companies at Arizona State ... intensive startup accelerator designed to help them execute their ... local jobs as part of ASU’s Edson Student ... offers approximately 20 student teams up to $20,000 each ... launch their for-profit, more-than-profit or nonprofit ventures. The program, ...

(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Migraines ... suffering, but new research indicates the combination of the ... a smaller brain. , , Already aware that people ... wanted to determine if having both conditions together affected ... 2 percent -- isn,t alarming, study authors said, but ...

(Date:5/22/2013)... May 22, 2013 Hurricane preparation isn’t ... home. That’s why Amica Insurance is reminding ... the upcoming hurricane season. , “An important part of ... Cook, a senior assistant vice president at Amica Insurance. ... before the threat of a storm.” , Flood damage ...

[0] Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners [0] Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort [0] Having Both Migraines, Depression May Mean Smaller Brain [0] Reviewing Insurance Policies: a Key Part of Hurricane Preparations

... LAS VEGAS, Jan. 8 (LVCC S227) ... a new initiative to make,radio more accessible to ... people around the world., At a press ... Vegas,the three organizations announced the global accessible radio ...

... Slumping Economy &, Presidential Election May Mean for Private Equity in ... ... With credit markets in,turmoil, the economy in a seeming slowdown and ... Equity Analyst Outlook,Conference on January 29-30 at the Grand Hyatt in New ...

... most common indication worldwide for pediatric transplantation, biliary atresia ... disease in newborns. Recently, Childrens Hospital of Pittsburgh of ... with biliary atresia face that lead to the need ... children undergoing their first liver transplant are diagnosed with ...

... population growth since the beginning of the XXth Century, ... slave trade and colonization. The regions population in fact ... in 2005. The latest United Nations projections, published in ... billion inhabitants being reached between the present and 2050., ...

... and improves ... customer ... subsidiary of Hays plc., one of the world,s leading specialist,recruitment ... processes and improve customer service., Hays stated that it ...

... MONTVALE, N.J., Jan. 8 Jennifer J. Day, Senior ... announces the,addition of Kenneth A. Sylvia as publisher of ... the healthcare industry who brings to DHM,30 years of ... client bases we serve," Day said. DHM is a ...

Cached Medicine News:Health News:NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired 2 Health News:NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired 3 Health News:NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired 4 Health News:NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired 5 Health News:Private Equity's Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference 2 Health News:Children's Hospital physicians publish review of transplant issues in patients with biliary atresia 2 Health News:Sub-Saharan Africa: the population emergency 2 Health News:Sub-Saharan Africa: the population emergency 3 Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 2 Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 3 Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 4

NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired Private Equity's Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference Children's Hospital physicians publish review of transplant issues in patients with biliary atresia Sub-Saharan Africa: the population emergency Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing Kenneth A. Sylvia Named as New Publisher of Current Psychiatry

... is suspected, every minute counts. ... allows rapid determination of the ... a single whole blood sample. ... within minutes - saving you ...

... Endoscopic cases it is extremely popular to combine ... Light. This combination affords the surgeon optimal ... an uncomfortable pose. The Dual Light System ... System. As such the light can be ...

... offers all the performance of a major surgical ... use in Outpatient Settings, Minor Procedure Rooms, C-Section, ... single lights either side of the OR table ... General OR when combining Flat Screen LCD Monitors ...

A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....

Medicine Products:

TROPT Sensitive NUVO Surgical Light - Double Light Head Monitor Ready NUVO Surgical Light - Single Light Head Anti-Myelin Associated Glycoproteins (MAG) Western Blot